Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Lobbying Update: $15,000 of AXOGEN INC. lobbying was just disclosed

None

$15,000 of AXOGEN INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Issues relating to sensation loss after mastectomy."

You can find more data on corporate lobbying on Quiver Quantitative.

AXGN Insider Trading Activity

AXGN Insider Trades

AXGN insiders have traded $AXGN stock on the open market 36 times in the past 6 months. Of those trades, 0 have been purchases and 36 have been sales.

Here’s a breakdown of recent trading of $AXGN stock by insiders over the last 6 months:

  • WILLIAM P. MR. BURKE has made 0 purchases and 13 sales selling 132,463 shares for an estimated $2,821,444.
  • MICHAEL D DALE (Chief Executive Officer) has made 0 purchases and 2 sales selling 86,463 shares for an estimated $2,668,137.
  • JOHN JOHNSON has made 0 purchases and 4 sales selling 45,379 shares for an estimated $1,390,392.
  • KATHY JOHNSON WEILER has made 0 purchases and 3 sales selling 46,653 shares for an estimated $1,378,475.
  • AMY MCBRIDE WENDELL has made 0 purchases and 3 sales selling 43,684 shares for an estimated $1,280,465.
  • LINDSEY MARIE HARTLEY (CFO) has made 0 purchases and 3 sales selling 29,199 shares for an estimated $896,298.
  • JOSEPH A. TYNDALL has made 0 purchases and 2 sales selling 25,108 shares for an estimated $777,770.
  • MARC A BEGAN (EVP & General Counsel) has made 0 purchases and 2 sales selling 22,500 shares for an estimated $686,207.
  • PAUL THOMAS sold 21,399 shares for an estimated $633,709
  • ERICK WAYNE DEVINNEY (Chief Innovation Officer) has made 0 purchases and 2 sales selling 20,654 shares for an estimated $627,608.
  • JENS KEMP (Chief Marketing Officer) sold 8,156 shares for an estimated $254,532

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

AXGN Hedge Fund Activity

We have seen 97 institutional investors add shares of AXGN stock to their portfolio, and 82 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

AXGN Analyst Ratings

Wall Street analysts have issued reports on $AXGN in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • HC Wainwright & Co. issued a "Buy" rating on 12/05/2025
  • Mizuho issued a "Outperform" rating on 12/01/2025
  • Canaccord Genuity issued a "Buy" rating on 10/30/2025
  • Citizens issued a "Market Outperform" rating on 10/30/2025
  • Raymond James issued a "Outperform" rating on 10/30/2025

To track analyst ratings and price targets for AXGN, check out Quiver Quantitative's $AXGN forecast page.

AXGN Price Targets

Multiple analysts have issued price targets for $AXGN recently. We have seen 7 analysts offer price targets for $AXGN in the last 6 months, with a median target of $37.0.

Here are some recent targets:

  • Yi Chen from HC Wainwright & Co. set a target price of $39.0 on 12/05/2025
  • Caitlin Cronin from Canaccord Genuity set a target price of $37.0 on 12/05/2025
  • Frank Takkinen from Lake Street set a target price of $40.0 on 12/04/2025
  • Michael Sarcone from Jefferies set a target price of $36.0 on 12/04/2025
  • Anthony Petrone from Mizuho set a target price of $40.0 on 12/01/2025
  • David Turkaly from Citizens set a target price of $34.0 on 10/30/2025
  • Jayson Bedford from Raymond James set a target price of $27.0 on 10/30/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles